Quantum Biopharma ( (TSE:QNTM) ) has shared an announcement.
Quantum BioPharma has appointed Kevin Malone as an advisor to its Board of Directors, bringing his extensive experience in stock trading and market manipulation to the company. This strategic move aligns with Quantum’s mission to combat stock manipulation practices such as naked short selling, which Malone has actively opposed. His appointment is expected to bolster Quantum’s efforts in this area while supporting its ongoing work in developing treatments for multiple sclerosis and other disorders.
More about Quantum Biopharma
Quantum BioPharma is a biopharmaceutical company focused on developing innovative biotech solutions for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. The company is actively engaged in the research and development of its lead compound, Lucid-MS, which targets multiple sclerosis. Quantum BioPharma also holds a strategic investment portfolio and retains significant ownership in Celly Nutrition, which markets the OTC product unbuzzd™.
YTD Price Performance: 52.94%
Average Trading Volume: 2,820,994
Technical Sentiment Signal: Buy
Current Market Cap: $14.13M
For an in-depth examination of QNTM stock, go to TipRanks’ Stock Analysis page.